Transgenic Mice for the Translational Study of Neuropathic Pain and Dystonia

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Aug 12

PMID 35955710

Authors

Damiana Scuteri

Kengo Hamamura

Chizuko Watanabe

Paolo Tonin

Giacinto Bagetta

Maria Tiziana Corasaniti

Affiliations

Soon will be listed here.

Abstract

Murine models are fundamental in the study of clinical conditions and the development of new drugs and treatments. Transgenic technology has started to offer advantages in oncology, encompassing all research fields related to the study of painful syndromes. Knockout mice or mice overexpressing genes encoding for proteins linked to pain development and maintenance can be produced and pain models can be applied to transgenic mice to model the most disabling neurological conditions. Due to the association of movement disorders with sensitivity and pain processing, our group focused for the first time on the role of the torsinA gene GAG deletion-responsible for DYT1 dystonia-in baseline sensitivity and neuropathic responses. The aim of the present report are to review the complex network that exists between the chaperonine-like protein torsinA and the baseline sensitivity pattern-which are fundamental in neuropathic pain-and to point at its possible role in neurodegenerative diseases.

Citing Articles

Advancing Pain Understanding and Drug Discovery: Insights from Preclinical Models and Recent Research Findings.

Asiri Y, Moni S, Ramar M, Chidambaram K Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598351 PMC: 11597627. DOI: 10.3390/ph17111439.

Current advancement in the preclinical models used for the assessment of diabetic neuropathy.

Saini T, Mazumder P Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(5):2727-2745.

PMID: 37987794 DOI: 10.1007/s00210-023-02802-0.

References

Lang T, Bruns D, Wenzel D, Riedel D, Holroyd P, Thiele C . SNAREs are concentrated in cholesterol-dependent clusters that define docking and fusion sites for exocytosis. EMBO J. 2001; 20(9):2202-13. PMC: 125434. DOI: 10.1093/emboj/20.9.2202. View

Downs A, Fan X, Kadakia R, Donsante Y, Jinnah H, Hess E . Cell-intrinsic effects of TorsinA(ΔE) disrupt dopamine release in a mouse model of TOR1A dystonia. Neurobiol Dis. 2021; 155:105369. PMC: 8327367. DOI: 10.1016/j.nbd.2021.105369. View

Sharma N, Baxter M, Petravicz J, Bragg D, Schienda A, Standaert D . Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J Neurosci. 2005; 25(22):5351-5. PMC: 6725000. DOI: 10.1523/JNEUROSCI.0855-05.2005. View

Vanni V, Puglisi F, Bonsi P, Ponterio G, Maltese M, Pisani A . Cerebellar synaptogenesis is compromised in mouse models of DYT1 dystonia. Exp Neurol. 2015; 271:457-67. DOI: 10.1016/j.expneurol.2015.07.005. View

DAngelo V, Paldino E, Cardarelli S, Sorge R, Fusco F, Biagioni S . Dystonia: Sparse Synapses for D2 Receptors in Striatum of a DYT1 Knock-out Mouse Model. Int J Mol Sci. 2020; 21(3). PMC: 7037849. DOI: 10.3390/ijms21031073. View

Washburn S, Fremont R, Moreno-Escobar M, Angueyra C, Khodakhah K . Acute cerebellar knockdown of reproduces salient features of myoclonus-dystonia (DYT11) in mice. Elife. 2019; 8. PMC: 6959989. DOI: 10.7554/eLife.52101. View

Scuteri D, Morrone L, Rombola L, Avato P, Bilia A, Corasaniti M . Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Clinical Evidence and Possible Mechanisms. Evid Based Complement Alternat Med. 2017; 2017:9416305. PMC: 5390566. DOI: 10.1155/2017/9416305. View

Scuteri D, Piro B, Morrone L, Corasaniti M, Vulnera M, Bagetta G . The need for better access to pain treatment: learning from drug consumption trends in the USA. Funct Neurol. 2018; 22(4):229-230. PMC: 5762109. DOI: 10.11138/fneur/2017.32.4.229. View

Zhao C, Brown R, Chase A, Eisele M, Schlieker C . Regulation of Torsin ATPases by LAP1 and LULL1. Proc Natl Acad Sci U S A. 2013; 110(17):E1545-54. PMC: 3637692. DOI: 10.1073/pnas.1300676110. View

10.

Mogil J, Grisel J . Transgenic studies of pain. Pain. 1998; 77(2):107-128. DOI: 10.1016/S0304-3959(98)00093-1. View

11.

Scuteri D, Hamamura K, Sakurada T, Watanabe C, Sakurada S, Morrone L . Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence. Front Pharmacol. 2021; 12:640128. PMC: 7957371. DOI: 10.3389/fphar.2021.640128. View

12.

Balcioglu A, Kim M, Sharma N, Cha J, Breakefield X, Standaert D . Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem. 2007; 102(3):783-8. DOI: 10.1111/j.1471-4159.2007.04590.x. View

13.

Alles S, Smith P . Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev. 2018; 70(2):315-347. DOI: 10.1124/pr.117.014399. View

14.

DAngelo V, Giorgi M, Paldino E, Cardarelli S, Fusco F, Saverioni I . A2A Receptor Dysregulation in Dystonia DYT1 Knock-Out Mice. Int J Mol Sci. 2021; 22(5). PMC: 7962104. DOI: 10.3390/ijms22052691. View

15.

Maldonado R, Banos J, Cabanero D . Usefulness of knockout mice to clarify the role of the opioid system in chronic pain. Br J Pharmacol. 2017; 175(14):2791-2808. PMC: 6016633. DOI: 10.1111/bph.14088. View

16.

Wilkes B, DeSimone J, Liu Y, Chu W, Coombes S, Li Y . Cell-specific effects of Dyt1 knock-out on sensory processing, network-level connectivity, and motor deficits. Exp Neurol. 2021; 343:113783. PMC: 8324325. DOI: 10.1016/j.expneurol.2021.113783. View

17.

DAngelo V, Castelli V, Giorgi M, Cardarelli S, Saverioni I, Palumbo F . Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of Dystonia. J Neurosci. 2017; 37(8):2112-2124. PMC: 6705690. DOI: 10.1523/JNEUROSCI.3207-15.2016. View

18.

Jiang M, Gold M, Boulay G, Spicher K, Peyton M, Brabet P . Multiple neurological abnormalities in mice deficient in the G protein Go. Proc Natl Acad Sci U S A. 1998; 95(6):3269-74. PMC: 19731. DOI: 10.1073/pnas.95.6.3269. View

19.

Dolphin A . Voltage-gated calcium channels and their auxiliary subunits: physiology and pathophysiology and pharmacology. J Physiol. 2016; 594(19):5369-90. PMC: 5043047. DOI: 10.1113/JP272262. View

20.

Soeder A, Kluger B, Okun M, Garvan C, Soeder T, Jacobson C . Mood and energy determinants of quality of life in dystonia. J Neurol. 2009; 256(6):996-1001. DOI: 10.1007/s00415-009-5060-3. View